Uncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2.
نویسندگان
چکیده
Erik B. van den Akker, Steven J. Pitts, Joris Deelen, Matthijs H. Moed, Shobha Potluri, Jeroen van Rooij, H. Eka D. Suchiman, Nico Lakenberg, Wesley J. de Dijcker, André G. Uitterlinden, Robert Kraaij, Albert Hofman, Anton J. M. de Craen, Jeanine J. Houwing-Duistermaat, Gert-Jan B. van Ommen on behalf of the Genome of The Netherlands Consortium, David R. Cox, Joyce B. J. van Meurs, Marian Beekman, Marcel J. T. Reinders, and P. Eline Slagboom
منابع مشابه
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.
Chronic myelomonocytic leukemia is a heterogeneous disease with multifactorial molecular pathogenesis. Various recurrent somatic mutations have been detected alone or in combination in chronic myelomonocytic leukemia. Recently, recurrent mutations in spliceosomal genes have been discovered. We investigated the contribution of U2AF1, SRSF2 and SF3B1 mutations in the pathogenesis of chronic myelo...
متن کاملSingle Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis
We hypothesized that analysis of single nucleotide polymorphism arrays (SNP-A) and new molecular defects may provide new insight in the pathogenesis of systemic mastocytosis (SM). SNP-A karyotyping was applied to identify recurrent areas of loss of heterozygosity and bidirectional sequencing was performed to evaluate the mutational status of TET2, DNMT3A, ASXL1, EZH2, IDH1/IDH2 and the CBL gene...
متن کاملMutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
We evaluated the association of mutations in 34 candidate genes and response to azacitidine in 84 patients with myelodysplastic syndrome (MDS), with 217 somatic mutations identified by next-generation sequencing. Most patients (93%) had ≥1 mutation (mean=2.6/patient). The overall response rate to azacitidine was 42%. No clinical characteristic was associated with response to azacitidine. Howeve...
متن کاملMutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.
Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia. Large-scale mutation profiling efforts in de novo myelodysplastic syndromes have identified mutations that correlate with clinical features, but such mutations have not been investigated in therapy-related myelodysplastic syndromes and...
متن کاملMYELOID NEOPLASIA Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia
To evaluate the prognostic value of genetic mutations for acute myeloid leukemia (AML) patients, we examined the gene status for both fusion products such as AML1 (CBF )–ETO, CBF MYH11, PML-RAR , and MLL rearrangement as a result of chromosomal translocations and mutations in genes including FLT3, C-KIT, N-RAS, NPM1, CEBPA, WT1, ASXL1, DNMT3A, MLL, IDH1, IDH2, and TET2 in 1185 AML patients. Cli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 127 11 شماره
صفحات -
تاریخ انتشار 2016